← Back to Search

Virus Therapy

PSMA-Targeted Trillium Compounds + PTI-122 for Prostate Cancer

Q: How many participants are currently enlisted in this research endeavor?

<p>Affirmative. Referring to clinicaltrials.gov, it is evident that this research project was initially launched on December 8th 2022 and recently updated on March 15th 2023. The study requires 36 people across 3 sites to fulfill its recruitment goal.</p>

Q: Is the research project currently open to new participants?

<p>Affirmative. Per the listing on clinicaltrials.gov, this research study is currently recruiting patients; it was initially posted December 8th 2022 and last updated March 15th 2023. The trial necessitates 36 participants at 3 different sites.</p>

Phase < 1

Waitlist Available

Research Sponsored by Ratio Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up over 168 hours post-injection

Awards & highlights

Study Summary

This trial studies how a drug affects prostate cancer in adult males. 36 people will get the drug, more may be added to the study if needed.

Eligible Conditions

Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ over 168 hours post-injection

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~over 168 hours post-injection

This trial's timeline: 3 weeks for screening, Varies for treatment, and over 168 hours post-injection for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Amount of radioactivity in blood

Amount of radiotracer absorbed by organs

Amount of radiotracer absorbed by tumor

Secondary outcome measures

Amount of PTI-122 in blood

Incidence of adverse events

Trial Design

3Treatment groups

Experimental Treatment

Group I: Trillium Compound AloneExperimental Treatment1 Intervention

Single dose of PSMA-Targeted [In-111]-Labeled Trillium Compound

Group II: Trillium Compound + Single Dose PTI-122Experimental Treatment2 Interventions

Single dose of PSMA-Targeted [In-111]-Labeled Trillium Compound plus single dose of PTI-122 at 5, 10 or 15 mg

Group III: Trillium Compound + Multiple Dose PTI-122Experimental Treatment2 Interventions

Single dose of PSMA-Targeted [In-111]-Labeled Trillium Compound plus two doses of PTI-122 at the preferred dose level

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

PSMA-Targeted [In-111]-Labeled Trillium Compound

2022

Completed Early Phase 1

~30

PTI-122

2022

Completed Early Phase 1

~30

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Ratio Therapeutics, Inc.Lead Sponsor

John Babich, PhDStudy DirectorRatio Therapeutics, Inc.

Media Library

PSMA-Targeted [In-111]-Labeled Trillium Compound (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05773703 — Phase < 1

Prostate Cancer Research Study Groups: Trillium Compound Alone, Trillium Compound + Single Dose PTI-122, Trillium Compound + Multiple Dose PTI-122

Prostate Cancer Clinical Trial 2023: PSMA-Targeted [In-111]-Labeled Trillium Compound Highlights & Side Effects. Trial Name: NCT05773703 — Phase < 1

PSMA-Targeted [In-111]-Labeled Trillium Compound (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05773703 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are currently enlisted in this research endeavor?

"Affirmative. Referring to clinicaltrials.gov, it is evident that this research project was initially launched on December 8th 2022 and recently updated on March 15th 2023. The study requires 36 people across 3 sites to fulfill its recruitment goal."

Answered by AI

Is the research project currently open to new participants?

"Affirmative. Per the listing on clinicaltrials.gov, this research study is currently recruiting patients; it was initially posted December 8th 2022 and last updated March 15th 2023. The trial necessitates 36 participants at 3 different sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer

2022. "Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05773703.